POAI (Predictive Oncology) יחס שווי שוק לשווי בספרים

The market dynamics of Predictive Oncology (POAI) reflected in the price action demonstrate current indicators at -0.06. Predictive Oncology focuses on partnerships with pharma behemoths, offering intelligent analysis of biosamples to assess the success of anti-tumor treatments. Revenue is based on the sale of subscriptions to the PeDAL system for digital drug modeling. Meanwhile, tests generate short-term profit, while long-term projects for discovering new molecules drive strategic growth.

This ratio determines the market value premium over the company's net assets. It measures the gap between the exchange price and the book value of capital, identifying whether the business is overvalued or undervalued. The price action of the market-to-book ratio allows for tracking investor sentiment regarding the value of resources. For Predictive Oncology (POAI), this metric reflects expectations for the commercialization of its developments. Sustained demand for medtech makes this indicator key to assessing the fundamental value of the company.